Stada pleased with difficult 2009 results
This article was originally published in Scrip
Stada's chairman Hartmut Retzlaff has said that last year was good for the company despite difficult conditions on the German market and negative effects of currency exchange rates. Strong international sales, which accounted for around two thirds of the total, contributed most to the success, he added.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.